Table 3.
Summary table of the ANOVA applied to protocol 2 data
| Trial type | TPJ group |
hMT/V5+ group |
Vertex group |
||||||
|---|---|---|---|---|---|---|---|---|---|
| ΔTE ± SEM (ms) | TMS F(1,20) | TMS × MD F(3,20) | ΔTE ± SEM (ms) | TMS F(1,20) | TMS × MD F(3,20) | ΔTE ± SEM (ms) | TMS F(1,20) | TMS × MD F(3,20) | |
| TMS-100 | |||||||||
| −g | −12.6 (9.1) | 1.8 | 0.6 | −23.6 (3.9) | 41.7** | 2.2 | −1.1 (5.9) | 0.03 | 0.09 |
| g | −33.6 (8.9) | 15.1** | 1.6 | −7.9 (2.7) | 4.7* | 0.5 | −4.8 (5.1) | 0.93 | 1.4 |
| TMS-300 | |||||||||
| −g | 3.0 (10.6) | 0.07 | 1.7 | −4.8 (6.7) | 0.5 | 1.3 | −2.9 (4.6) | 0.28 | 0.06 |
| g | −2.7 (6.8) | 0.15 | 1.2 | 2.6 (3.1) | 0.93 | 2.9 | −2.2 (5.8) | 0.14 | 0.98 |
The parameters reported are the same as in Table 2. Statistically significant effects are indicated in bold. *p < 0.05; **p < 0.001.